AbbVie has reached settlements with all generic drugmakers to resolve litigation that challenged their plans to introduce generics of its arthritis drug Rinvoq, per an MSN report. The generic drug ...
AbbVie continues to project low single-digit growth through 2030 as it expands its immunology franchise and makes a major ...
- Updated indication allows the use of RINVOQ ® (upadacitinib) prior to the use of tumor necrosis factor (TNF) blocking agents in patients for whom use of these treatments is clinically inadvisable ...
NORTH CHICAGO, Ill., April 29, 2025 /PRNewswire/ -- AbbVie (ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved RINVOQ ® (upadacitinib), 15 mg, once daily, for the treatment ...
MedPage Today on MSN
Not All Drugs Approved for Rheumatoid Arthritis Are Equal for Pain Relief
Both upadacitinib (Rinvoq) and adalimumab (Humira) are proven effective in rheumatoid arthritis (RA) and psoriatic arthritis ...
Both Skyrizi and its cousin Rinvoq have landed in the annual top three, in varying positions, since 2022. That was once again the case in 2025, when Skyrizi retained its place at the top and Rinvoq ...
NORTH CHICAGO, Ill., Oct. 29, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive topline results from two replicate Phase 3 studies evaluating the safety and efficacy of upadacitinib ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback